钠-葡萄糖共转运蛋白-2抑制剂对2型糖尿病肾脏结局的影响:三级中心经验

IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Mohammed H. Tawhari, Raed A. Aldahash, Faisal M. Almutairi, Mahdi S. Albogami, Ahmad E. Rokon, Faisal A. Alsomali, Khaled H. Alanazi, Abdulrahman A. Alshehri, Talal H. Almutairi, Abdulrahman D. Alharbi, Rayan M. Alghamdi, Ibrahim H. Tawhari, Salih A. Bin Salih
{"title":"钠-葡萄糖共转运蛋白-2抑制剂对2型糖尿病肾脏结局的影响:三级中心经验","authors":"Mohammed H. Tawhari, Raed A. Aldahash, Faisal M. Almutairi, Mahdi S. Albogami, Ahmad E. Rokon, Faisal A. Alsomali, Khaled H. Alanazi, Abdulrahman A. Alshehri, Talal H. Almutairi, Abdulrahman D. Alharbi, Rayan M. Alghamdi, Ibrahim H. Tawhari, Salih A. Bin Salih","doi":"10.4103/jfcm.jfcm_111_23","DOIUrl":null,"url":null,"abstract":"BACKGROUND: Diabetic nephropathy (DN) is a complication of chronic hyperglycemia associated with diabetes mellitus (DM). Several studies have demonstrated the positive impact of sodium-glucose cotransporter-2 (SGLT2) inhibitors on kidney outcomes. The objective of the study was to evaluate the effects of dapagliflozin, an SGLT2 inhibitor, on kidney outcomes in Saudi patients with type 2 DM. MATERIALS AND METHODS: Study included all Saudi patients with type 2 DM who visited our center from August 1, 2021, to July 31, 2022, and had been on dapagliflozin for at least 3 months. Data was abstracted through chart review for all patients included in the study. Paired t-test or Wilcoxon signed-rank test were used to compare the results before and after treatment for continuous variables and the McNemar test was used to compare the results for categorical data. RESULTS: Study included 184 Saudi patients with type 2 diabetes with a mean age of 61.32 years (SD=9.37). Dapagliflozin 10 mg/day significantly reduced hemoglobin A1C (HbA1C) from a mean (SD) of 9.00 to 8.40 ( P < 0.001). Among a subgroup of patients with significant proteinuria ( n = 83), dapagliflozin significantly reduced ACR from a median of 93.1 to 64.9 mg/g ( P = 0.001). Following treatment, the estimated glomerular filtration rate improved from a mean of 69.83 to 71.68 mL/min and the mean arterial pressure (MAP) fell from 90.03 to 89.06 mmHg, both were not statistically significant. Despite a statistically insignificant increase in the episodes of urinary tract infections (UTIs), the hospitalization rate declined. No episodes of amputations or ketoacidosis occurred during the study period. CONCLUSION: SGLT2 inhibitors had beneficial effects among Saudi patients with type 2 diabetes by improving diabetic control and lowering proteinuria. Dapagliflozin did not result in significant harm, including UTIs, amputations, and ketoacidosis.","PeriodicalId":46862,"journal":{"name":"Journal of Family and Community Medicine","volume":"128 1","pages":"0"},"PeriodicalIF":1.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of sodium-glucose cotransporter-2 inhibitors on kidney outcomes in type 2 diabetes: A tertiary center experience\",\"authors\":\"Mohammed H. Tawhari, Raed A. Aldahash, Faisal M. Almutairi, Mahdi S. Albogami, Ahmad E. Rokon, Faisal A. Alsomali, Khaled H. Alanazi, Abdulrahman A. Alshehri, Talal H. Almutairi, Abdulrahman D. Alharbi, Rayan M. Alghamdi, Ibrahim H. Tawhari, Salih A. Bin Salih\",\"doi\":\"10.4103/jfcm.jfcm_111_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND: Diabetic nephropathy (DN) is a complication of chronic hyperglycemia associated with diabetes mellitus (DM). Several studies have demonstrated the positive impact of sodium-glucose cotransporter-2 (SGLT2) inhibitors on kidney outcomes. The objective of the study was to evaluate the effects of dapagliflozin, an SGLT2 inhibitor, on kidney outcomes in Saudi patients with type 2 DM. MATERIALS AND METHODS: Study included all Saudi patients with type 2 DM who visited our center from August 1, 2021, to July 31, 2022, and had been on dapagliflozin for at least 3 months. Data was abstracted through chart review for all patients included in the study. Paired t-test or Wilcoxon signed-rank test were used to compare the results before and after treatment for continuous variables and the McNemar test was used to compare the results for categorical data. RESULTS: Study included 184 Saudi patients with type 2 diabetes with a mean age of 61.32 years (SD=9.37). Dapagliflozin 10 mg/day significantly reduced hemoglobin A1C (HbA1C) from a mean (SD) of 9.00 to 8.40 ( P < 0.001). Among a subgroup of patients with significant proteinuria ( n = 83), dapagliflozin significantly reduced ACR from a median of 93.1 to 64.9 mg/g ( P = 0.001). Following treatment, the estimated glomerular filtration rate improved from a mean of 69.83 to 71.68 mL/min and the mean arterial pressure (MAP) fell from 90.03 to 89.06 mmHg, both were not statistically significant. Despite a statistically insignificant increase in the episodes of urinary tract infections (UTIs), the hospitalization rate declined. No episodes of amputations or ketoacidosis occurred during the study period. CONCLUSION: SGLT2 inhibitors had beneficial effects among Saudi patients with type 2 diabetes by improving diabetic control and lowering proteinuria. Dapagliflozin did not result in significant harm, including UTIs, amputations, and ketoacidosis.\",\"PeriodicalId\":46862,\"journal\":{\"name\":\"Journal of Family and Community Medicine\",\"volume\":\"128 1\",\"pages\":\"0\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Family and Community Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jfcm.jfcm_111_23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Family and Community Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jfcm.jfcm_111_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

背景:糖尿病肾病(DN)是慢性高血糖与糖尿病(DM)相关的并发症。一些研究已经证明了钠-葡萄糖共转运蛋白-2 (SGLT2)抑制剂对肾脏预后的积极影响。该研究的目的是评估SGLT2抑制剂达格列净对沙特2型糖尿病患者肾脏结局的影响。材料和方法:研究纳入了2021年8月1日至2022年7月31日期间到访我们中心并服用达格列净至少3个月的所有沙特2型糖尿病患者。通过对纳入研究的所有患者的图表回顾提取数据。对连续变量采用配对t检验或Wilcoxon符号秩检验比较治疗前后的结果,对分类数据采用McNemar检验比较结果。结果:研究纳入184例沙特2型糖尿病患者,平均年龄61.32岁(SD=9.37)。达格列净10mg /天显著降低血红蛋白A1C (HbA1C),从平均(SD) 9.00降至8.40 (P <0.001)。在有显著蛋白尿的患者亚组(n = 83)中,达格列净显著降低ACR,中位数从93.1 mg/g降至64.9 mg/g (P = 0.001)。治疗后,估计肾小球滤过率从平均69.83 mL/min提高到71.68 mL/min,平均动脉压(MAP)从90.03 mmHg下降到89.06 mmHg,两者均无统计学意义。尽管尿路感染(uti)的发生率在统计上没有显著增加,但住院率却有所下降。研究期间未发生截肢或酮症酸中毒。结论:SGLT2抑制剂对沙特2型糖尿病患者具有改善糖尿病控制和降低蛋白尿的有益作用。达格列净没有造成重大伤害,包括尿路感染、截肢和酮症酸中毒。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of sodium-glucose cotransporter-2 inhibitors on kidney outcomes in type 2 diabetes: A tertiary center experience
BACKGROUND: Diabetic nephropathy (DN) is a complication of chronic hyperglycemia associated with diabetes mellitus (DM). Several studies have demonstrated the positive impact of sodium-glucose cotransporter-2 (SGLT2) inhibitors on kidney outcomes. The objective of the study was to evaluate the effects of dapagliflozin, an SGLT2 inhibitor, on kidney outcomes in Saudi patients with type 2 DM. MATERIALS AND METHODS: Study included all Saudi patients with type 2 DM who visited our center from August 1, 2021, to July 31, 2022, and had been on dapagliflozin for at least 3 months. Data was abstracted through chart review for all patients included in the study. Paired t-test or Wilcoxon signed-rank test were used to compare the results before and after treatment for continuous variables and the McNemar test was used to compare the results for categorical data. RESULTS: Study included 184 Saudi patients with type 2 diabetes with a mean age of 61.32 years (SD=9.37). Dapagliflozin 10 mg/day significantly reduced hemoglobin A1C (HbA1C) from a mean (SD) of 9.00 to 8.40 ( P < 0.001). Among a subgroup of patients with significant proteinuria ( n = 83), dapagliflozin significantly reduced ACR from a median of 93.1 to 64.9 mg/g ( P = 0.001). Following treatment, the estimated glomerular filtration rate improved from a mean of 69.83 to 71.68 mL/min and the mean arterial pressure (MAP) fell from 90.03 to 89.06 mmHg, both were not statistically significant. Despite a statistically insignificant increase in the episodes of urinary tract infections (UTIs), the hospitalization rate declined. No episodes of amputations or ketoacidosis occurred during the study period. CONCLUSION: SGLT2 inhibitors had beneficial effects among Saudi patients with type 2 diabetes by improving diabetic control and lowering proteinuria. Dapagliflozin did not result in significant harm, including UTIs, amputations, and ketoacidosis.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Family and Community Medicine
Journal of Family and Community Medicine PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
4.00
自引率
3.70%
发文量
20
审稿时长
37 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信